Press Release
healthHealthcarePharmaceuticals

Erectile Dysfunction Drugs Market will be Grow at a CAGR of 4.5% Between 2013 and 2019

According to a new market report published by Transparency Market Research Erectile Dysfunction Drugs Market (Viagra, Cialis, Levitra/Staxyn, Stendra/Spedra, Zydena, MUSE, Mvix and Helleva) –Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013  2019, the global erectile dysfunction drugs market was valued at USD 4.3 billion in 2012 and is expected to decline at a CAGR of (4.5%) from 2013 to 2019, to reach an estimated value of USD 3.4 billion in 2019.

The global market for erectile dysfunction drugs has been studied from the perspective of currently marketed branded drugs and pipeline drugs. Branded drugs include Viagra (sildenafil citrate), Cialis (tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil), MUSE (medicated urethral systems for erection), Mvix (mirodenafil) and Helleva (lodenafil). The drugs in the pipeline for erectile dysfunction treatment primarily consist of two major drugs, namely Vitaros (alprostadil) and Uprima (apomorphine) currently in later phases of clinical trials.

Request for Discount:

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1550

A few novel compounds are currently under investigation in both preclinical and clinical settings, for the treatment of impotency. These studies are majorly focused on medications with improved efficacy, shorter onset of action and fewer side effects as compared to the currently available treatments. Such pipeline drugs include Vitaros (alprostadil), Uprima (apomorphine) and Topiglan (alprostadil), amongst others.

Geographically, North America dominated the global market for erectile dysfunction drugs in terms of revenue generation and is expected to maintain its position throughout the forecast period. The extended patent exclusivity for Pfizer’s Viagra (sildenafil citrate) in the U.S., till 2020, will be responsible for the leadership of the North American market. Europe was the second largest regional market for erectile dysfunction drugs in 2012, owing to the increased demand for ED drugs. Market growth will also be facilitated by the expected marketing approvals for a few promising drug candidates such as Stendra/Spedra (avanafil) and Zydena (udenafil) by mid 2014.

The global erectile dysfunction dugs market is dominated by few major players including Pfizer, Inc. Eli Lilly & Co., and Bayer AG. Post patent expiration of the major branded drugs and intense genericization of the market, the competition in this market is expected to be characterized by consolidation activities, partnerships, and intensive mergers and acquisitions. The other key players in the erectile dysfunction drugs market include Dong-A Pharmaceutical Co. Ltd., Vivus, Inc., Apricus Biosciences, Inc. and Meda Pharmaceuticals.

Request Multiple Chapters:

https://www.transparencymarketresearch.com/sample/sample.php?flag=MC&rep_id=1550

Tags

Related Articles

Close